Studies into depression and agitation and aggression will play a key role in helping to reduce inappropriate prescriptions of antipsychotics for people with dementia.
The June 2011 edition of the Brain Waves newsletter is available to download from the Innovations in Dementia website.
The NHS Institute for Innovation and Improvement and the Dementia Action Alliance have launched a call to action to work together to improve the quality of life of people with dementia and their carers by reducing the inappropriate use of antipsychotics for these people.
A new clinic to help find a treatment for Alzheimer’s disease will be set up in Bristol after a £1 million grant was made to researchers.
This dataset from the NHS Information Centre provides information about Primary Care Trust (PCT) prescribing data between January and March 2011.
The innovative approach means that new, better treatments could be available in just seven years, bringing hope to people with dementia and their carers.
Lithium treatment may slow the development of dementia, according to a study published in the British Journal of Psychiatry (Wednesday 27 April 2011).
The final NICE guidance means the drugs Aricept, Exelon and Reminyl will be available on prescription to people in the early and moderate stages of Alzheimer’s and Ebixa will be available to people in the late stages.
Details of a letter from Sir Ian Carruthers, Chief Executive of NHS South West and Jeremy Hughes, Chief Executive of the Alzheimer’s Society, to SHA Chief Executives to invite them to adapt four recommendations to drive down inappropriate prescribing antipsychotic medication and providing alternative ways of working and interventions that improve the safety, quality of life and outcomes for people with dementia.
Sir Ian Carruthers, Chief Executive of NHS South West, recently wrote to South West Chief Executives and South West Directors of Adult Social Care outlining the next steps on implementing the four national priorities set out in Quality outcomes in dementia.